SG11201805605TA - Compositions and methods for detecting and treating ovarian cancer - Google Patents

Compositions and methods for detecting and treating ovarian cancer

Info

Publication number
SG11201805605TA
SG11201805605TA SG11201805605TA SG11201805605TA SG11201805605TA SG 11201805605T A SG11201805605T A SG 11201805605TA SG 11201805605T A SG11201805605T A SG 11201805605TA SG 11201805605T A SG11201805605T A SG 11201805605TA SG 11201805605T A SG11201805605T A SG 11201805605TA
Authority
SG
Singapore
Prior art keywords
international
ovarian cancer
compositions
methods
pct
Prior art date
Application number
SG11201805605TA
Other languages
English (en)
Inventor
Alexandre Prieur
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of SG11201805605TA publication Critical patent/SG11201805605TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201805605TA 2015-12-31 2017-01-02 Compositions and methods for detecting and treating ovarian cancer SG11201805605TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307192 2015-12-31
EP16305138 2016-02-05
PCT/EP2017/050033 WO2017114972A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating ovarian cancer

Publications (1)

Publication Number Publication Date
SG11201805605TA true SG11201805605TA (en) 2018-07-30

Family

ID=57821943

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805605TA SG11201805605TA (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating ovarian cancer

Country Status (13)

Country Link
US (1) US11760808B2 (cg-RX-API-DMAC7.html)
EP (2) EP3954999B9 (cg-RX-API-DMAC7.html)
JP (2) JP6962920B2 (cg-RX-API-DMAC7.html)
KR (2) KR102428254B1 (cg-RX-API-DMAC7.html)
CN (2) CN108780091A (cg-RX-API-DMAC7.html)
AU (2) AU2017204682B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018013271A2 (cg-RX-API-DMAC7.html)
CA (2) CA3009751A1 (cg-RX-API-DMAC7.html)
EA (1) EA037015B1 (cg-RX-API-DMAC7.html)
ES (2) ES2901602T3 (cg-RX-API-DMAC7.html)
PL (1) PL3397964T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201805605TA (cg-RX-API-DMAC7.html)
WO (1) WO2017114972A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018264A1 (en) * 2015-12-31 2024-01-18 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ecs前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
JP7687224B2 (ja) * 2022-01-25 2025-06-03 株式会社三洋物産 遊技機
JP7687223B2 (ja) * 2022-01-25 2025-06-03 株式会社三洋物産 遊技機

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2008157383A1 (en) * 2007-06-15 2008-12-24 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
WO2011116954A2 (en) 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
CA3009751A1 (en) 2017-07-06
US20190002582A1 (en) 2019-01-03
JP6962920B2 (ja) 2021-11-05
JP7279761B2 (ja) 2023-05-23
JP2019502923A (ja) 2019-01-31
AU2021250840A1 (en) 2021-11-04
AU2017204682B2 (en) 2021-07-29
CA3194356C (en) 2025-04-08
EP3954999B9 (en) 2025-03-12
EP3397964B1 (en) 2021-09-29
KR102507685B1 (ko) 2023-03-08
EP3954999A1 (en) 2022-02-16
EP3397964A1 (en) 2018-11-07
BR112018013271A2 (pt) 2018-12-11
KR102428254B1 (ko) 2022-08-03
EA201891529A1 (ru) 2019-01-31
EP3954999B1 (en) 2025-01-15
US11760808B2 (en) 2023-09-19
ES2901602T3 (es) 2022-03-23
AU2021250840B2 (en) 2024-06-27
CN122150588A (zh) 2026-06-05
ES3015244T3 (en) 2025-04-30
WO2017114972A1 (en) 2017-07-06
EP3954999C0 (en) 2025-01-15
KR20180105647A (ko) 2018-09-28
CN108780091A (zh) 2018-11-09
JP2022009080A (ja) 2022-01-14
KR20220100100A (ko) 2022-07-14
AU2017204682A1 (en) 2018-07-19
CA3194356A1 (en) 2017-07-06
EA037015B1 (ru) 2021-01-27
PL3397964T3 (pl) 2022-02-07

Similar Documents

Publication Publication Date Title
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201908888VA (en) Compositions and methods for treating lung cancer
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201908998XA (en) Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201805001UA (en) Method of treating influenza a
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof